All Biotherapeutics articles
-
NewsNew target found for glaucoma treatment
Scientists have discovered that specialised immune cells in the eye help keep its drainage system clear and regulate pressure, which could inform new treatments for glaucoma.
-
ArticleEngineering the next generation of T-cell engagers
T-cell engagers are a branch of immunotherapy that has undergone considerable change since their clinical inception. Andrew J Souers, VP, Oncology Discovery Research at AbbVie, elucidates the current understanding of their biology and expanding focus areas of application.
-
NewsBrain discovery could improve drugs targeting amyloid diseases
New research shows the brain can intentionally form amyloids to store memories, challenging decades of thinking about neurodegenerative disease and pointing towards new strategies for drug discovery.
-
NewsELRIG announces keynote speakers for Cell and Gene Therapy 2026 in Cambridge
ELRIG (European Laboratory Research & Innovation Group) has announced the keynote speakers for its inaugural Cell and Gene Therapy 2026 conference, taking place at Hinxton Hall in Cambridge from 9–10 March.
-
NewsVirus-mimicking LENN nanoparticles deliver mRNA to bladder cancer cells
Researchers have developed virus-inspired LENN nanoparticles that deliver mRNA therapies directly to bladder cancer cells, remain stable after freeze-drying and avoid triggering immune responses.
-
ArticleDisrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
-
NewsClaudin 18.2-targeted therapy advances GI cancer treatment
A novel imaging-guided radiopharmaceutical targeting claudin 18.2 has shown that it can precisely detect and effectively treat gastric and pancreatic tumours, completely eradicating cancer in some preclinical models.
-
ArticleFertility beyond IVF: therapeutic advances in reproductive biotech
Procedural advances in IVF are reaching their biological limits. Reproductive biotech is now moving upstream, developing first in class therapeutics that target meiosis, gamete quality and implantation biology as druggable mechanisms in early discovery.
-
NewsEngineered extracellular vesicles control immune responses
Researchers have engineered new extracellular vesicles that can selectively induce antigen-specific regulatory T cells, possibly leading towards safer, more precise treatments for autoimmune and allergic diseases.
-
ArticlePeptides in practice: what it takes to advance these therapies to clinic
Peptide therapeutics are emerging as a powerful class of medicines capable of targeting diseases that challenge traditional modalities. This article reveals their rising clinical impact and the key development, safety and translational challenges that must be addressed to bring them successfully to patients.
-
ArticleWhy patient-derived biology matters for ADC discovery
What can we learn from tumours after they stop responding to treatment? By studying patient tissue directly, researchers are finding new ADC targets that conventional screening often misses.
-
ArticleBuilding better biologics and a stronger future for women in STEM
Great biologics don’t happen by chance, and neither do great STEM careers. Dr Lidia Serina shares the lessons behind both.
-
NewsTY1: new experimental drug restores tissue after heart attack
Scientists have developed an experimental RNA-based drug, TY1, that repairs DNA, reduces scar tissue and could lead to new treatments for heart attacks and autoimmune diseases.
-
NewsNew CAR-NKT treatment destroys metastatic pancreatic tumours
A novel CAR-NKT immunotherapy developed at UCLA has shown striking success in preclinical models of metastatic pancreatic cancer, which could hopefully lead to more accessible treatments.
-
NewsNew mRNA therapy targets drug-resistant pneumonia
A new mRNA therapy that prompts the body to produce bacteria-killing ‘peptibodies’ has shown early success in preclinical models, offering a potential new tool in the fight against antibiotic-resistant pneumonia.
-
NewsSamsung invests in Phrontline to advance next-gen ADC therapies
Samsung Life Science Fund has made a strategic equity investment in clinical-stage biotechnology company Phrontline Biopharma, supporting the development of next-generation antibody-drug conjugates (ADCs).
-
NewsBlood stem cell and islet cell transplant combo reverses type 1 diabetes
Stanford researchers have cured Type 1 diabetes in mice using a combination of blood stem cell and pancreatic islet cell transplants.
-
NewsScientists use AI to create antibodies entirely from scratch
Scientists at the University of Washington’s Institute for Protein Design have used artificial intelligence to create antibodies entirely from scratch, a breakthrough that could reshape drug discovery.
-
ArticleRecombinant KLK1: the next step in stroke and preeclampsia treatment
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to restore blood flow, improve endothelial function and address unmet needs in the treatment of stroke and preeclampsia.
-
NewsEnzyme PapB could boost diabetes and obesity peptide drugs
Researchers have discovered an enzyme, PapB, that can ‘tie off’ therapeutic peptides into stable rings, which could help improve GLP-1 drugs for diabetes and obesity – making them more effective and longer lasting.